In Brief NAM New Voices Program for emerging STEM leaders announces 2026 cohort February 13, 2026Vol.52 No.06
In Brief Curebound adds five business leaders to board to accelerate cancer research February 13, 2026Vol.52 No.06
Clinical Roundup Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds February 13, 2026Vol.52 No.06
Clinical Roundup Rural cancer patients do just as well as urban patients when having surgery close to home, study finds February 13, 2026Vol.52 No.06
Clinical Roundup AI tool may help personalize ovarian cancer treatment from day one February 13, 2026Vol.52 No.06
Clinical Roundup HPV cancer vaccine slows tumor growth, extends survival in animal models February 13, 2026Vol.52 No.06
Clinical Roundup Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology February 13, 2026Vol.52 No.06
Drugs & Targets FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma February 13, 2026Vol.52 No.06
Drugs & Targets FDA approves companion diagnostic for pembrolizumab for ovarian cancer February 13, 2026Vol.52 No.06
Conversation with The Cancer Letter On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center February 06, 2026Vol.52 No.05By Paul Goldberg
